You are here: Industry Insights > Pradaxa

News List

FDA Approves First Oral Blood Thinner for Children americanpharmaceuticalreview
June 23, 2021
The U.S. FDA approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood ...
FDA OKs First Oral Blood Thinning Medication for Children drugs
June 23, 2021
The first oral blood thinning medication for children was approved by the U.S. Food and Drug Administration, the agency announced Monday.
FDA Approves Pradaxa (dabigatran) as First Oral Blood Thinning Medication for Children drugs
June 22, 2021
Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly
FDA Approves First Oral Blood Thinning Medication for Children fda.gov
June 22, 2021
Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients worldpharmanews
September 02, 2019
Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients...